Corixa, Wyeth re-write adjuvant deal

1 November 2001

Corixa and Wyeth Lederle Vaccines have extended their existing MPLadjuvant license agreement to include the former's Ribi-529 adjuvant, to be used in vaccines to prevent or treat a variety of diseases, including certain infections and one autoimmune disorder. Under the terms of the new agreement, Corixa will supply Wyeth with the Ribi-529 and MPL adjuvants in exchange for an undisclosed transfer price, and will also receive license fees, annual license and minimum royalty payments, plus royalties based on product sales. Further financial details were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight